Novo Nordisk Stock Falls Despite Strong Q3 Weight-Loss Drug Sales: Retail Shrugs Off Weakness
Novo Nordisk’s injectable weight-loss drug Wegovy sales climbed 79% year-over-year but overall sales growth was a touch soft.
Tap the Weight-Loss Drug Market With These ETFs
The weight-loss drug market is heating up with the introduction of GLP-1 pills. Novo Nordisk’s NVO Wegovy and Eli Lilly’s LLY Zepbound have been dominating this market and several other companies are...